Brain metastases develop following the spread of cells from a primary tumour through the blood (haematogenous seeding) to the brain microvasculature, although seeding from established metastases might also occur. Complex microenvironmental niche–tumour interactions, neuroinflammatory cascades and, possibly, neovascularization are involved in establishing a new metastasis (colonization).
“Brain Metastasis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Brain Metastasis market. A detailed picture of the Brain Metastasis pipeline landscape is provided, which includes the disease overview and Brain Metastasis treatment guidelines.
The assessment part of the report embraces in-depth Brain Metastasis commercial assessment and clinical assessment of the Brain Metastasis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Metastasis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
View report: https://www.delveinsight.com/sample-request/brain-metastasis-pipeline-insight
About Disease
- Brain metastases can often be the cause of the initial presenting symptoms in patients with otherwise previously undiagnosed advanced-stage cancer. The majority of brain metastases result from lung, breast and colorectal cancer (CRC), melanoma and renal cell carcinoma (RCC), although brain metastases from other tumour types (including haematological cancers) have been reported.
- Metastases are the most common tumours of the central nervous system (CNS), but cancer databases are often incomplete leading to underestimation of the incidence of even symptomatic brain metastases. Brain imaging studies are not routinely performed on neurologically asymptomatic cancer patients and autopsy studies are outdated. Furthermore, while incidence rates for cancers are stable and mortality is decreasing due to earlier detection and better therapy, the incidence of brain metastases appears to be increasing.
Brain Metastasis of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Brain Metastasis with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Brain Metastasis treatment.
- Brain Metastasis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Brain Metastasis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Brain Metastasis Analytical Perspective by DelveInsight
- In-depth Brain Metastasis Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Brain Metastasis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Request for sample pages: https://www.delveinsight.com/sample-request/brain-metastasis-pipeline-insight
Scope of the report
- The Brain Metastasis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Brain Metastasis across the complete product development cycle, including all clinical and non-clinical stages.
- It comprises of detailed profiles of Brain Metastasis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Brain Metastasis research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Brain Metastasis.
Table of contents:
1. Report Introduction
2. Brain Metastasis
2.1. Overview
2.2. History
2.3. Brain Metastasis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Brain Metastasis Diagnosis
2.6.1. Diagnostic Guidelines
3. Brain Metastasis Current Treatment Patterns
3.1. Brain Metastasis Treatment Guidelines
4. Brain Metastasis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Brain Metastasis Late Stage Products (Phase-III)
7. Brain Metastasis Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Brain Metastasis Discontinued Products
13. Brain Metastasis Product Profiles
14. Brain Metastasis Key Companies
15. Brain Metastasis Key Products
16. Dormant and Discontinued Products
17. Brain Metastasis Unmet Needs
18. Brain Metastasis Future Perspectives
19. Brain Metastasis Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Download report: https://www.delveinsight.com/sample-request/brain-metastasis-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/